CYP1A2 and breast cancer: CYP1A2 is able to metabolize some polycyclic aromatic hydrocarbons (PAHs), a procarcinogen, to carcinogenic intermediates, so that higher CYP1A2 activity may influence the risk of lung cancer and breast cancer [36, 37].